Rethinking the economic costs of hospitalization for malaria: accounting for the comorbidities of malaria patients in western Kenya

Caroline Watts1,2*, Harrysone Atieli3, Jason Alacapa4, Ming-Chieh Lee5, Guofa Zhou5, Andrew Githeko6, Guiyun Yan5 and Virginia Wiseman1,7

Abstract
Background: Malaria causes significant mortality and morbidity in sub-Saharan Africa, especially among children under five years of age and places a huge economic burden on individuals and health systems. While this burden has been assessed previously, few studies have explored how malaria comorbidities affect inpatient costs. This study in a malaria endemic area in Western Kenya, assessed the total treatment costs per malaria episode including comorbidity in children and adults.

Methods: Total economic costs of malaria hospitalizations were calculated from a health system and societal perspective. Patient-level data were collected from patients admitted with a malaria diagnosis to a county-level hospital between June 2016 and May 2017. All treatment documented in medical records were included as health system costs. Patient and household costs included direct medical and non-medical expenses, and indirect costs due to productivity losses.

Results: Of the 746 patients admitted with a malaria diagnosis, 64% were female and 36% were male. The mean age was 14 years (median 7 years). The mean length of stay was three days. The mean health system cost per patient was Kenyan Shilling (KSh) 4288 (USD 42.0) (95% confidence interval (CI) KSh 4046–4531). The total household cost per patient was KSh 1676 (USD 16.4) (95% CI KSh 1488–1864) and consisted of: KSh 161 (USD1.6) medical costs; KSh 728 (USD 7.1) non-medical costs; and KSh 787 (USD 7.7) indirect costs. The total societal cost (health system and household costs) per patient was KSh 5964 (USD 58.4) (95% CI KSh 5534–6394). Almost a quarter of patients (24%) had a reported comorbidity. The most common malaria comorbidities were chest infections, diarrhoea, and anaemia. The inclusion of comorbidities compared to patients without comorbidities led to a 46% increase in societal costs (health system costs increased by 43% and patient and household costs increased by 54%).

Conclusions: The economic burden of malaria is increased by comorbidities which are associated with longer hospital stays and higher medical costs to patients and the health system. Understanding the full economic burden of malaria is critical if future malaria control interventions are to protect access to care, especially by the poor.

Keywords: Malaria, Coinfection, Healthcare costs, Kenya, Africa

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
While there has been a worldwide decline in the number of cases and deaths over the last decade, in 2017 there were an estimated 219 million cases of malaria, and malaria control strategies continue to place a significant economic burden on many resource-constrained health systems, especially those in sub-Saharan Africa [1]. Annually in Kenya, there are an estimated 3.5 million cases diagnosed and 10,700 deaths from malaria, of which children constitute 67% [1]. Kenya has had a national strategy in place since 2004 with guidelines for vector control, malaria management in pregnancy, and strategies to improve diagnosis and treatment [1, 2]. Many endemic countries like Kenya also face increasing malaria incidence due to changing climatic and farming practices, particularly deforestation [3] as well as resistance to pyrethroid insecticides [4].

Ensuring ‘affordable’ malaria treatment is a stated priority in the malaria control strategy of the Kenyan Government [5]. Notable initiatives include the abolition of user fees at primary healthcare facilities [6] and a range of malaria control programmes in areas of high malaria endemicity, including the distribution of insecticide-treated nets (ITNs), free treatment for pregnant women and children under 5 years with malaria [7], communication strategies to encourage testing [8] and the appropriate use of anti-malarial medication, intermittent preventive treatment in pregnancy (IPTp) which includes anti-malarial drugs at antenatal check-ups and a free ITNs, and the provision of indoor residual spraying (IRS) in high risk areas. Treatment for malaria is free at public hospitals and based on a recommended dosage schedule according to weight and age [9, 10]. Complicated malaria requires specialized case management depending on clinical presentation [10]. While, health insurance is available, coverage in Kenya remains low and often does not cover outpatient services such as diagnostic testing or medications [11]. As hospitals operate on cost sharing arrangements, some informal user fees and dispensary charges still apply in hospitals [6, 11].

In Kenya, malaria is the most common reason for presentation at local hospitals [12], and together with diarrhoea and pneumonia are the most common causes of death in infants under 5 years [1]. Decisions about seeking healthcare are often related to the perceived degree of morbidity risk [13, 14] and hence, it is not unusual for patients to present to hospital for treatment with more than one underlying condition [15, 16]. Some conditions such as anaemia (which is included in the national strategy for malaria control), are known to be associated with both malaria and helminth infections [17, 18]. Studies examining the co-endemicity of these infections have found that increased worm burden infection is associated with increased malaria parasitaemia [17, 18]. Other conditions, such as respiratory infections share similar symptoms to malaria, making it difficult to differentiate the cause of illness and can cause delays in seeking treatment as a respiratory infection may be expected to resolve without treatment [19]. Antibiotic use associated with diagnostic-confirmed malaria remains common [20]. Children presenting with malaria and gastrointestinal symptoms such as diarrhoea have been found to have significantly longer hospital stays than those who did not (3.13 ± 1.78 versus 2.66 ± 1.38 days) [21] and influenza has been shown to increase hospital stays by 1–3 days in settings where the typical stay was 3–5 days [22].

The economic burden of malaria inpatient and outpatient care has been well-researched, and studies on household costs have found malaria imposes significant financial burden on households [23, 24]. However, few studies in Kenya have examined the extent to which such comorbidities affect the cost of malaria treatment [25]. Ensuring affordable malaria treatment is a stated priority in Kenya’s Malaria Operational Plan [2], and health promotion messages advise patients to promptly seek confirmatory testing and use artemisinin-based combination therapy (ACT) if malaria is diagnosed [26]. The United Nations Sustainable Goals [27] note that infants and young children are more likely to be affected by malaria, and hence these families will experience greater financial burden when caregivers must take time away from paid and unpaid activities when their children are ill [20, 28]. Excluding costs of malaria comorbidities, may underestimate the actual cost of malaria-related hospitalizations [29] and mask the financial burden experienced by patients and their families [30–32]. This study assessed the comorbidities associated with malaria and their impact on hospitalization costs, from a health system and societal perspective.

Methods
Study setting
This study used patient-level data from Iguhu hospital, a sub-county hospital in Kakamega county, in the malaria endemic-prone Western Kenya highlands. The hospital is funded by the Kakamega County Government Health serving a population of 17,860 people. It has 21 beds and 4 cots catering for children, women, and men. Critically ill patients are transferred to Kakamega County Teaching and Referral Hospital in Kakamega township 16 km away. The majority of the population work in small-scale subsistence farming keeping livestock, growing corn and tea or work in the informal sector [33]. Water catchments are used for agricultural purposes. Comprising both
endemic and highland-epidemic prone areas, the topography, climate and farming methods favour high rates of malaria transmission [9]. A sample of children in Kakamega county found levels of parasitaemia in Kakamega to be 33%, well above the national average of 8% [34].

Study sample
The sample comprised all infants, children, adolescents and adults admitted to Iguhu hospital with a diagnosis of malaria, associated symptoms such as fever, malaise, headache or vomiting and a laboratory confirmed Plasmodium-positive blood smear (or positive RDT test if laboratory testing was not available) between June 2016 and May 2017.

Cost data collection
An ingredients-based approach [35] was used to estimate the health system and household costs of diagnosing and managing malaria hospitalizations. Patient and household costs were classified as: (1) direct costs (or out-of-pocket costs) subdivided into medical and non-medical costs; and (2) indirect costs. Direct medical costs included payments for hospital fees, medications and non-medical costs such as transport, meals and the costs of funerals for malaria related deaths. Indirect costs—including lost productive time due to travelling to hospital, being ill or providing care to a sick child—were estimated for adults over the age of 18 years using the human capital approach [36], taking a subsistence wage for an agricultural worker [37] and multiplying it by the lost time.

Measures
To estimate resource use, detailed data were collected from hospital admission records which included: patient age, sex, village of residence, sublocation, pregnancy status, type of malaria diagnostic test conducted, type of malaria treatment, any other diagnostic tests and treatments, length of stay, discharge destination; and any fees paid by patients for their inpatient stay. Key personnel from Iguhu hospital advised on specific costs for patients, including hospital charges, transport and food, provision and stock-outs of medications in the past 12 months, and the approximate costs of these medications at local village vendors.

Health system costs
Health system cost data were extracted from patient-level medical records and included costs associated with hospitalization (bed cost), laboratory tests, medications and related overheads (Additional file 1: Table S1). Health system costs were classified into four categories: bed day cost and a diagnostic test for malaria on admission, management of malaria, management of comorbidities, such as diarrhoea and anaemia excluding antibiotics; and antibiotics for management of infection.

Bed cost
Inpatient cost per bed day was obtained from WHO “choosing interventions that are cost-effective (WHO-CHOICE)” framework [38]. These country-specific estimates are based on a primary level hospital with few specialties and between 30 and 200 beds and include all personnel, capital and accommodation costs excluding medications and tests. The cost per inpatient day was inflated to 2020 prices and averaged over 12 months [39]. This bed cost was multiplied by length of stay which was extracted from inpatient records.

Laboratory test for malaria
All inpatients had confirmed malaria and the cost of microscopic diagnosis was derived from previously published estimates for Kenya [25].

Medications for management of malaria and additional treatment
As the hospital records only listed the names of medications, dosage calculations for malaria were based on Kenya of Government National Malaria Treatment Guidelines [10] for the malaria components, and for other illnesses based on recommended dosage and duration documented in the Kenya Essential Medicines List [40], Médecins Sans Frontières (MSF) Essential Drugs [41], and MSF Clinical Guidelines [42] based on diagnosis. When recommended dosages were based on a child’s weight, approximate weights for age were calculated using the WHO weight for age charts [43] and costs were estimated based on manufacturer formulations and pack size. Dosages were independently calculated by CW and JA. When an antibiotic was recorded but an additional diagnosis was not documented (10% cases), the most frequent diagnosis for persons of a similar age in the dataset who were also prescribed that antibiotic was used to estimate dosage.

The costs of medications and equipment were estimated using the Kenya Medical Supplies Authority (KEMSA) price list [40]. KEMSA is funded through the Ministry of Health and is responsible for the procurement and sales of essential medicines and medical supplies to government health facilities. For drugs not included on the KEMSA list, a mean cost was calculated using the Kenya Drug-Index [44]. The costs of microscopy to detect parasites in blood samples used to confirm a diagnosis of malaria were based on previously published estimates [25].
All medications listed in the hospital records and administration costs (disposable needles and syringes, IV giving sets) were included. For an additional diagnosis of dehydration, the cost for the insertion of an intravenous line and 24 h of IV fluids was included. For anaemia, where blood was required, it was assumed that one unit of packed cells was used [45], and that any oral supplements prescribed were administered for the duration of inpatient stay.

**Patient and household costs**

**Direct medical costs**

Direct patient costs included: registration books, laboratory test for malaria on admission and any hospital fees documented in hospital records. Children under five years of age and pregnant women were exempted from paying a registration fee and fees for malaria laboratory tests. Hospital inpatient charges to patients were included as recorded in the patient record. Any inpatient charges were assumed to be paid at discharge and deducted from the total health system cost.

Costs for medication following discharge were based on prices in the Iguhu hospital pharmacy medications price manual [46]. Hospitals set their own price for medications dispensed to discharged patients and outpatients. If the drug was not listed in the manual, the price in the KEMSA price list was doubled to reflect the price ratio in the pharmacy manual.

**Direct non-medical costs**

Travel costs of patients and any accompanying persons were estimated for motorbike taxi transport. If the patient was a child under 6 years of age it was assumed that a caregiver travelled to and from the hospital with them and a meal was purchased each day. If a patient had to be transferred to Kakamega, an additional cost was estimated for a return trip. In the case of death, funeral costs were also included.

Discounting was not necessary as all costs were estimated over one year. Any costs from the published literature were converted to local currency, Kenyan Shilling (KSh) and adjusted for inflation to 2020. Changes over time in the prices of non-medical goods and services were adjusted using the Kenya consumer price index (CPI) [39], and medical costs were adjusted using the Kenyan CPI for Health [47], and then converted to USD [48].

**Statistical analysis**

Patient-level data were transferred securely in a Microsoft Excel format and analysis was performed using SAS 9.4 (SAS Institute, Cary NC). Patient characteristics are described with chi-square tests used to calculate differences in proportions. Sensitivity analysis was conducted to examine the impact on household costs of an increase in hospital costs due to inflation (5%); and the impact of stockouts of antibiotics as this was reported to be a common issue by hospital personnel. If antibiotics were not available from the hospital, it was assumed they would be purchased from a local vendor. The percentage difference between the public sector (hospitals) and private sector (pharmacies) procurement prices for locally produced and imported medicines (expressed as median price ratios) [49] was used to estimate the cost increase in antibiotics if they were purchased from a local vendor. To reflect usual availability of medicines, the proportion of imported medicines (55%) and locally produced medicines (45%) were also taken into account [49]. Based on these assumptions, the price of antibiotics in the private sector was estimated to be 158% higher than in the public sector. It was assumed antibiotics were in stock 66% of the time based on the reported availability of general medicines in the public sector [49].

**Results**

The sample consisted of 746 inpatients, 478 (64%) females and 268 (36%) males. The mean age for patients was 14.5 years, median 7 years (IQR 2.5–21). The median age for females was 11 years (IQR 3.4–30 years) and males 4 years (IQR: 2–9). There were 41 women admitted to hospital who were pregnant. Most patients (98%) were discharged home after the hospital stay, with 7 (1%) patient deaths and 9 (1%) hospital transfers (Table 1). Almost all individuals (98%) admitted to hospital were diagnosed with severe malaria. Intravenous artesunate was given to 98% of patients, with the remaining patients (2%) receiving quinine (intravenous or oral) or oral artesunate.

Of the patients admitted, 179 (24%) had a documented comorbidity in addition to malaria. Younger patients (< 5 years) were more likely to have comorbidities compared to older patients (p = 0.02) (Additional file 1: Table S2). Patients with one or more comorbidities were more likely to stay longer than three days (p < 0.001). Gender was not associated with a reported comorbidity (Additional file 1: Table S1). Of the comorbidities reported within this patient group, 22% (38/171) were diarrhoea, 16% (27/171) upper respiratory tract infection, 15% (26/171) anaemia, and 14% (24/171) pneumonia (Additional file 1: Table S3). Antibiotic use was documented for 61% (104/171) of patients and was generally consistent across all groups, ranging from 13% of inpatients in the 5 ≤ 12 years and >12 years age groups to 16% of children up to 5 years.

Of this patient group, 614 patients (82%) incurred some direct costs. These included 167 patients who only paid registration or laboratory costs (27%) and 229 patients
(37%) who paid a hospital inpatient fee of KSh 100 (USD 1). Both of these fees were paid by 209 patients (34%) and nine patients (2%) paid higher fees between KSh 200-KSh 850. (Additional file 1: Table S3). Five pregnant women paid a hospital inpatient fee.

The mean health system cost was KSh 4288 (USD 42.0) (95% confidence interval (CI) 95% CI KSh 4046–4531). Total patient and household costs averaged KSh 1676 (USD 16.4) (95% CI KSh 1488-1864) per patient, consisting of KSh 161 (USD1.6) medical and KSh 728 (USD 7.1) non-medical costs and KSh 787 (USD 7.7) indirect costs. The total societal cost (health system and household costs) was KSh 5964 (USD 58.4) (95% CI KSh 5534–6394) (Table 2).

**Accounting for additional illness**
Comparing patients with no comorbidities to patients experiencing one or more comorbidities, for patients with comorbidities the mean health system costs per patient increased by 43% from KSh 3877 (USD 38.0) to KSh 5538 (USD 54.3), respectively. Total mean patient and household costs increased by 54% from KSh 1480 (USD 14.5) to KSh 2281 (USD 22.4), of which direct costs increased by 80% from KSh 743 (USD 7.3) to KSh 1,337 (USD 13.1), and indirect costs due to productivity losses increased by 22% from KSh 737 (USD 7.2) to KSh 945 (USD 9.3) (Fig. 1; Table 2). Societal costs were 46% higher for admissions with at least one comorbidity in addition to malaria, compared to malaria only diagnoses (Fig. 1; Table 2).

Overall, 27% of patients were in hospital longer than the average length of stay of three days. If patients who were in hospital for three days or less, were compared with patients who stayed longer than three days, health system costs were 47% higher, increasing from KSh 3468 (USD 34.0) to KSh 6560 (USD 64.3). Total mean patient and household costs increased by 57% from KSh 1480 (USD 14.5) to KSh 2281 (USD 22.4) of which direct costs increased by 29% from KSh 825 (USD 8.1) to KSh 1062 (USD 10.4) per patient and productivity losses increased by 48% from KSh 631 (USD 6.2) to KSh 1220 (USD 12.0) per patient (Fig. 1; Table 2). Societal costs were 80% higher for patients who had longer than average stays in hospital compared to patients who stayed three days or less in hospital (Fig. 1; Table 2).

**Sensitivity analysis**
Based on all patients (Table 2), a 5% increase in hospital and medicine costs increased societal costs by 4% to KSh 6186 (USD 60.6). Antibiotics availability in hospitals 66% of the time would decrease health system costs by 0.4% to KSh 4272 (USD 41.9) and increase total patient and household costs by 7% to KSh 1797 (USD 17.6), due to the 14% increase in direct medical costs which increased from KSh 889 (USD 8) to KSH 1010 (USD 9.9). Overall, the societal cost was increased by 2% to KSh 6102 (USD 59.7) (Additional file 1: Table S4). Antibiotics availability in hospitals 10%-34% of the time would increase total patient and household costs by 11%-9 % respectively (Additional file 1: Table S4).

**Discussion**
The costs associated with a visit to hospital for malaria represent a significant cost to the Kenyan health care system and to patients in malaria-endemic areas, such as Igugu. Almost a quarter of patients admitted with malaria had at least one additional illness. While the inclusion of additional treatment provided during a hospital stay for malaria increased total health system costs the impact was greatest on household costs. Despite government policies to exempt payments for the treatment for children under 5 years and pregnant women, fees are still being incurred by these patients. Additional direct medical costs were incurred for medications and hospital
Table 2  Mean health system and patient costs (KSh) related to hospitalization with confirmed malaria diagnosis

| Description of cost | All patients n=746 | Patients with no comorbidity n=570 | Patients with one of more comorbidities n=176 | Hospital stay ≤ 3 days n=547 | Hospital stay > 3 days n=199 |
|---------------------|---------------------|------------------------------------|-----------------------------------------------|-----------------------------|-------------------------------|
|                     | Mean cost 95 %CI    | Mean cost 95 %CI                   | Mean cost 95 %CI                              | Mean cost 95 %CI            | Mean cost 95 %CI              |
| Health system cost  |                     |                                    |                                               |                             |                               |
| Hospital admission and bed cost1 | 2650 2574-2727 | 2552 2474-2631 | 2963 2770-3156 | 2145 2101-2188 | 4052 3923-4182 |
| Malaria management  | 1378 1331-1426 | 1324 1277-1372 | 1549 1427-1672 | 1137 1104-1170 | 2046 1937-2154 |
| Additional treatment2 | 212 109-306 | 0 - | 831 408-1253 | 158 54-262 | 363 98-628 |
| Antibiotics         | 47 32-62 | 0 - | 195 137-254 | 28 20-36 | 100 47-152 |
| Total health system cost | 4288 4046-4531 | 3877 3800-4053 | 5583 4785-6380 | 3468 3393-3639 | 6560 6054-7166 |
| Household costs     |                     |                                    |                                               |                             |                               |
| Direct costs        |                     |                                    |                                               |                             |                               |
| Registration, hospital fee | 118 111-125 | 119 111-128 | 113 103-122 | 120 113-129 | 111 100-123 |
| Antibiotics         | 41 29-52 | - - | 166 125-201 | 42 28-56 | 35 19-50 |
| Other medication    | 2 1-3 | - - | 8 4-12 | 2 1-3 | 3 1-6 |
| Non-medical costs   |                     |                                    |                                               |                             |                               |
| Transport & food cost | 599 558-640 | 551 507-495 | 741 648-834 | 511 475-547 | 844 733-955 |
| Funeral costs       | 129 34-225 | 73 0-155 | 308 7-609 | 151 30-271 | 70 0-207 |
| Subtotal direct costs | 889 733-1044 | 743 608-878 | 1337 887-1699 | 825 647-1005 | 1062 785-1339 |
| Indirect costs      |                     |                                    |                                               |                             |                               |
| Productivity loss   | 787 755-1044 | 737 703-772 | 945 822-960 | 631 601-655 | 1220 1149-1291 |
| Total household costs | 1676 1488-1864 | 1480 1311-1650 | 2281 1839-2502 | 1456 1252-1660 | 2283 1935-2630 |
| Total               | 5964 5534-6394 | 5357 5061-5654 | 7820 6500-9139 | 4923 4532-5316 | 8843 7940-9746 |

1 Hospital admission cost includes outpatient assessment and confirmation of malaria. If patient fees were charged, these costs were deducted and included as direct costs.

2 Additional treatment relates to costs for management of comorbidities excluding costs of antibiotics.
inpatient fees and non-medical costs for transport and food. Transportation costs were found to be a key driver of direct patient costs, as reported in several other studies [11, 50]. The additional cost for a hospital admission of USD 7 to patients and their households is significant, given that the average income in Kenya is less than USD 3 a day.

This data aligns with other studies examining inpatient costs of malaria treatment [23, 51, 52, 53]. The mean patient cost of USD 15.5 for an average length of three days stay is similar to those reported by Kodhiambo et al. [23], an estimate of USD 10 for two days stay which was obtained from parent surveys for children with a malaria diagnosis admitted to multiple level (Level II to Level IV) health facilities. The proportions of total household costs for direct medical and non-medical costs and indirect costs are quite similar between the two studies [23]. These results are also consistent with healthcare spending patterns described by Barasa et al. [11], who used the Kenya Household Expenditure and Utilization Survey and found that transport costs constituted one-third of direct inpatient costs, and also that for poorer households with limited disposable income, such costs could reduce household consumption and potentially have an impoverishing effect [11]. Household costs have also been found to increase where levels of malaria endemicity are highest, but the incremental effect of comorbidities on costs was not investigated [28]. These findings also align with the estimates of health system and direct household costs described by Sicuri et al. [52] for a hospital malaria admission without a comorbidity, however, their indirect costs are three times higher due to the inclusion of lifelong productivity losses [52], highlighting the economic impact of premature death. A study from Kenya that separated the cost of management of malaria from comorbidities, found that the addition of pneumonia increased the health system cost of hospitalization by 13% [25]. The overall health system costs for paediatric admissions in a Level IV hospital ranged from USD 47.2 to USD 75.2 in 2005, largely due to bed day costs and were much higher compared to this study [25].

There were a few limitations with this analysis. Firstly, costs may have been underestimated. Inpatient laboratory tests were not documented and therefore, not included in this cost analysis, but it can be assumed these costs would be minimal given an expectation of less complex inpatients in Level 3 hospitals. Also costs for patients who were transferred were not included as information about subsequent care or outcomes was not available. Costs may have also been missed if medications or additional medical conditions were not recorded by staff at the time of admission or discharge. Information about prior health-seeking behaviour, such as whether patients had presented on another day and been sent home, or if any other medications had been purchased prior to presenting at the hospital was not available. Secondly, shortages of general medicines in public hospitals in Kenya is not unusual [49], and was only examined in the sensitivity analysis based on general medicine shortages, rather than antibiotics which typically have lower availability [49], and hence, patient out-of-pocket costs associated with purchasing these medicine in the private retail sector may be underestimated. The use of hospital patient records, the hospital pharmacy medications and price list, and the KEMSA procurement price list meant that accurate data was obtained, avoiding recall bias which is sometimes an issue using household surveys to estimate costs [53, 54]. Thirdly, reductions in productivity may have been underestimated due to additional days not working at full capacity as it is likely that caregivers would have reduced capacity to work while also caring for children recuperating at home [24, 55]. Finally, as noted in the preceding paragraph this valuation did not include costs associated with lifelong productivity loss due to death from malaria.

Despite health financing reforms that have removed user fees in public primary health facilities and provided free maternity care [56], 82% of patients in this study admitted with malaria incurred a hospital fee which included 12% of pregnant women and around 30% of children aged under 5 years. Hospital fees were also reported in an earlier study of out-of-pocket costs for children aged under five years in Kenya [57] indicating hospital charges are still occurring in public health facilities. Out of pocket costs for patients who should be exempt from paying fees creates a risk of impoverishing families [11]. These costs can also deter people who are ill from seeking care, in turn increasing the incidence of severe disease and thus mortality [58]. Unfortunately, reasons for patient fees were not documented however.
hospital fees were on average slightly lower for patients with a comorbidity or with longer lengths of stay compared to the average patient, indicating some internal censoring of fees charged to patients, and that a portion of the fees may be waived for some patients who are more ill. Regardless, a comorbidity or longer length of stay meant that households incurred higher out-of-pocket costs for transport, food, and medicines.

Conclusions
Although the economic burden of malaria in Kenya has been assessed previously, most studies did not capture costs beyond the treatment of malaria and malaria sequelae. Comorbidities such as anaemia, diarrhoea and infections are common and increase treatment costs and length of stay, however the extent of this burden on the health system and households remains unclear. Further research is required to understand the true cost of a hospital admission for malaria in a range of malaria-endemic areas. Evidence on the aggregate inpatient costs of malaria and its comorbidities is important for designing interventions to improve access to treatment especially by the poor, and for conducting economic evaluations of these interventions.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12936-021-03958-x.

Acknowledgements
Brian Musalia, Alex Machanga, and the Iguhu hospital staff for their assistance with data collection.

Authors’ contributions
CW and VW conceived the study. CW analysed and interpreted the inpatient data. Dosages were independently calculated by CW and JA. All authors read and approved the final manuscript.

Funding
This work was supported by Grants from the National Institutes of Health (R01 AI050243, and D43 TW001505).

Availability of data and materials
The datasets generated during and/or analysed during the current study are not publicly available as the data are not publicly available due to them containing information that could compromise research participant privacy/consent but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was approved by the Ethical Review Board of Kenya Medical Research Institute (SSC protocol No3005) and county authority to access hospital records in Iguhu hospital. Individual patient consent was not sought, and identifying information was not collected.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 The Kirby Institute, University of New South Wales, Sydney, Australia. 2 Daffodil Centre, The University of Sydney, Cancer Council NSW, Sydney, Australia. 3 School of Public Health, Maseno University, Kisumu, Kenya. 4 The School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia. 5 Program in Public Health, University of California, Irvine, California, USA. 6 Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya. 7 London School of Hygiene & Tropical Medicine, London, UK.

Received: 29 May 2021 Accepted: 18 October 2021

Published online: 30 October 2021

References
1. WHO Global Malaria Programme. World Malaria Report. Geneva: World Health Organization, 2018.
2. Division of National Malaria Programme. National Malaria Control Programme. https://www.nmcp.or.ke/index.php. Accessed 8 Sept 2021.
3. Zhou G, Wiseman V, Atieli HE, Lee MC, Githelko AK, Yan G. The impact of long-lasting microbial larvicides in reducing malaria transmission and clinical malaria incidence: study protocol for a cluster randomized controlled trial. Trials. 2016;17:423.
4. Zhou G, Afrane YA, Vando-Zalik AM, Atieli H, Zhong D, Wampe P, et al. Changing patterns of malaria epidemiology between 2002 and 2010 in Western Kenya: the fall and rise of malaria. PLoS. 2011;6:e20318.
5. National Malaria Control Programme. Ministry of Health. Towards a malaria-free Kenya. Kenya Malaria Strategy 2019-2023. Kenya: Nairobi, 2019.
6. Maina T, Kiringa D. Annual evaluation of the abolition of user fees at primary healthcare facilities in Kenya. Washington DC: Futures Group, Health Policy Project, 2015.
7. National Malaria Control Programme. Malaria in pregnancy. Nairobi, Kenya. 2018. http://www.nmcp.or.ke/index.php.
8. National Malaria Control Programme. Ministry of Health. Kenya Malaria Communication Strategy 2016-2021. Kenya Nairobi; 2016.
9. National Malaria Control Programme (NMCP). Kenya National Bureau of Statistics (KNBS) and ICF International. 2015 Kenya Malaria Indicator Survey. Nairobi Kenya and Rockville Maryland USA; 2016.
10. Ministry of Public Health and Sanitation; Division of Malaria Control. National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya. Nairobi, Kenya; 2016.
11. Barasa EW, Maina T, Rav Shankar N. Assessing the impoverishing effects, and factors associated with the incidence of catastrophic health care payments in Kenya. Int J Equity Health. 2017;16:31.
12. Kapesa A, Kwesia EJ, Atieli H, Afrane YA, Kamuigisha E, Lee MC, et al. The current malaria morbidity and mortality in different transmission settings in Western Kenya. PLoS One. 2018;13:e0202031.
13. Etabe E, Onwujeke O, Uzochukwu B, Uguru N, Okonkwo I, Adjuga B. What co-morbidities do people with malaria have and what are their patterns of health seeking in Nigeria? Niger J Clin Pract. 2015;18:22–6.
14. Burton DC, Flannery B, Onyango B, Larson C, Alai J, Zhang X, et al. Healthcare-seeking behaviour for common infectious disease-related illnesses in rural Kenya: a community-based house-to-house survey. J Health Popul Nutr. 2011;29:61–70.
15. D’Acremont V, Kilowoko M, Kyungu E, Filipina S, Sangu W, Kahama-Maro J, et al. Beyond malaria - causes of fever in outpatient Tanzanian children. N Engl J Med. 2014;370:809–17.

16. Feikin DR, Olack B, Bigogho GM, Audi A, Cosmas L, Aura B, et al. The burden of common infectious disease syndromes at the clinic and household level from population-based surveillance in rural and urban Kenya. PLoS One. 2011;6:e16085.

17. Mulu A, Legesse M, Erko B, Belyhuyn Y, Njugusie D, Shireilis T, et al. Epidemiological and clinical correlates of malaria-helminth co-infections in Southern Ethiopia. Malar J. 2013;12:227.

18. Degarege A, Veledar E, Degarege D, Erko B, Nacher M, Madhivanan P. Plasmodium falciparum and soil-transmitted helminth co-infections among children in sub-Saharan Africa: a systematic review and meta-analysis. Parasit Vectors. 2016;9:344.

19. Herrick C, Cosmas L, Mogoni OD, Koli W, Mfmanza S, Loffredo C, et al. Health beliefs and patient perspectives of febrile illness in Kilombero, Tanzania. Am J Trop Med Hyg. 2019;10:263–70.

20. Hopkins H, Bruvo odor KJ, Cairns ME, Chandler CR, Levent B, Ansh UK, et al. Impact of introduction of rapid diagnostic tests for malaria on antibiotic prescribing: analysis of observational and randomised studies in public and private healthcare settings. BMJ. 2017;356:j1054.

21. LoVecchio A, Basile FW, Bruvo odor D, Di Dato F, Pol R, Omona V, et al. Diarrhoea in children with Plasmodium falciparum malaria: a case-control study on the prevalence and response to antimarial treatment. Am J Trop Med Hyg. 2021;104:659–65.

22. Thompson MG, Breiman RF, Hamel MJ, Desai M, Khagayi S, et al. The burden of malaria due to anti-malarial resistance. A systematic review. Malar J. 2011;10:337.

23. United Nations Sustainable Development Group. Sustainable development goals: an assessment of prevalence and risk factors in children from the Lake endemic region. Malar J. 2019;18:233.

24. Gunda R, Shamu S, Chimbari MJ, Mukaratirwa S. Economic burden of malaria in four sub-Saharan African countries: a case study. Health Action International; 2018.

25. Iguhu Hospital pharmacy. Iguhu Pharmacy Book. Kakamega: Iguhu Hospital; 2018.

26. Stenberg K, Lauer JA, Gkountouras G, Fitzpatrick C, Stanicole A. Econometric estimation of WHO-CHOICE country-specific costs for inpatient and outpatient health service delivery. Cost Eff Resour Alloc. 2018;16:11.

27. Kenya National Bureau of Statistics. Kenya Consumer Price Index (CPI) and Inflation rates http://www. knbs. ke/ consumer‑price‑indice/ . Accessed 21 Mar 2019.

28. Kenya. KEMSA. Kenya Essential Medicines List. 2017. http://www. kems a. coke/ salesprice‑list/ . Accessed 10 Dec 2018.

29. Médecins Sans Frontières. Clinical guidelines - diagnosis and treatment manual. MSF, 2019.

30. WHO. Weight for age. Geneva: World Health Organization. https://www. who. int/ child‑growth/ standards/ . Accessed 27/02/2019.

31. L M. A Blood Transfusion in Africa? It's Free in Rwanda, Unaffordable in Zimbabwe. https://globalpressjournal.com/africa/blood-transfusion-africa-free-rwanda-unaffordable-zimbabwe/. Accessed 4 Mar 2020.

32. Wattset al. Malar J. (2021) 20:429

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.